CD24: A Marker for an Extended Expansion Potential of Urothelial Cancer Cell Organoids In Vitro?

Ruizhi Geng 1,†, Niklas Harland 2,†, Ivonne A. Montes-Mojarro 3, Falko Fend 3, Wilhelm K. Aicher 1, Arnulf Stenzl 2 and Bastian Amend 2,*

1 Center for Medical Research, University Hospital, Eberhard Karls University, 72074 72072 Tuebingen, Germany; grz_880606@hotmail.com (R.G.); aicher@uni-tuebingen.de (W.K.A.)
2 Department of Urology, University of Tuebingen Hospital, 72076 Tuebingen, Germany; niklas.harland@med.uni-tuebingen.de (N.H.); urologie@med.uni-tuebingen.de (A.S.)
3 Institute for Pathology, Eberhard Karls University, 72074 Tuebingen, Germany; ivonne.montes@med.uni-tuebingen.de (I.A.M.-M.); falko.fend@med.uni-tuebingen.de (F.F.)
* Correspondence: bastian.amend@med.uni-tuebingen.de; Tel.: +49-7071-298-5092
† These authors contributed equally to this work.

Abstract: Background: Bladder cancer is the most cost-intensive cancer due to high recurrence rates and long follow-up times. Bladder cancer organoids were considered interesting tools for investigating better methods for the detection and treatment of this cancer. Methods: Organoids were generated from urothelial carcinoma tissue samples, then expanded and characterized; the expression of immune modulatory antigens and tumor stem cells markers CD24 and CD44 was explored in early (P ≤ 3) and later (P ≥ 5) passages (P) by immunofluorescence and by quantitative PCR of cDNA. The expression of these factors was investigated in the corresponding cancer tissue samples by immunohistochemistry. Results: The expression of the PD-L1 was detected on some but not all organoids. CD276 and CD47 were observed on organoids in all passages investigated. Organoids growing beyond passage 8 expressed both CD24 and CD44 at elevated levels in early and late cultures. Organoids proliferating to the eighth passage initially expressed both CD24 and CD44, but lost CD24 expression over time, while CD44 remained. Organoids growing only up to the 6th passage failed to express CD24 but expressed CD44. Conclusions: The data indicate that the expression of CD24 in urothelial cancer cell organoids may serve as an indicator for the prolonged proliferation potential of the cells.

Keywords: bladder cancer organoids; immune checkpoint antigens; CD24; CD44; bladder cancer stem-cell marker

1. Introduction

Bladder cancer (BC) is among the most common malignancies in many countries. A global incidence of more than 350,000 new cases and a prevalence of close to 3 million cases were estimated about a decade ago [1]. Current studies reported considerably higher incidences of more than 550,000 new cases per year [2]. The exposure of individuals to different pathogens and regular tobacco smoking have to be considered when discussing the cause of BC [3–5].

Besides behavioral and acquired risk factors, genetic disposition also contributes to BC [6]. Genome-wide screens including samples of cohorts of more than 3500 donors from several individual studies confirmed several gene loci associated with BC [7]. Mutations of genes common to most malignancies, for instance, factors controlling the cell cycle or cells death such as tumor protein P53, phosphatase and tensin homolog (PTEN), or loss of retinoblastoma (Rb) were also detected in BC samples [8].

Depending on the size and stage of development, tumors contain a blend of cells. A small cohort of cancer stem cells (CSC) is present in a specific tumor niche in most types of
primary cancers [9,10]. These CSCs contribute to the ignition of tumor development and to the growth of the tumor itself [11]. However, true CSCs are mitotically quiescent and may remain for extended periods of time in a G0 stage of the cell cycle [12]. They therefore differ significantly from proliferating tumor cells in sensitivities towards anti-cancer drugs aiming at DNA replication or the regulation of the cell cycle and apoptosis [13,14]. Cells in G0 are also less sensitive to radiation and immunotherapy [15]. While radiation acts on cells with physical injury, chemotherapy and even more so immunotherapy provoke effects on active compounds on or in cells targeted on a biochemical level. Many biochemical processes can be modified by a corresponding blocking agent. This applies for inflammatory or immunological action against a tumor as well. The evasion of tumor cells from immunorecognition was associated with elevated expression of immune checkpoint molecules such as programmed cell death-1 (PD-1, CD279), its ligand PD-L1 (CD274), cytotoxic T-lymphocyte associated protein-4 (CTLA-4, CD152), or the cell surface molecule B7-H3 (CD276) [16]. These factors modulate the activation of T lymphocytes by the tumor and thus contribute to the immune tolerance against cancer cells. Another pathway modulates the intrinsic immune system by overexpression of the integrin-associated signal transducer CD47. Activated macrophages may induce apoptosis in tumor cells [17]. CD47 expressing tumor cells are not effectively attacked by macrophages. Blocking CD47 facilitated phagocytosis of cancer cells and growth of urothelial carcinoma cells in immune-deficient mice [18,19]. In addition, CD47 was also considered a bladder cancer stem-cell marker [14,20].

Cancer stem cells are recognized by the expression of distinct stem-cell markers. These markers differ in CSCs of tumors of different origins [11]. In solid tumors, the expression of the sialoglycoprotein CD24, the cell surface glycoprotein CD44, the transmembrane protein CD133, and the adhesion molecules CD166 (ALCAM) and CD326 (EPCAM) were associated with CSCs. However, CD133, CD166 and CD326 were considered CSC markers for colorectal cancer [21,22]. The expression of CD133 in BC samples was discussed, but its expression was not confined to urothelial BC cells in vitro [23,24]. CD166 mutants were associated with an increased BC susceptibility, but expression of CD166 on BC stem cells was not explored [25]. As mentioned above, CD47 is considered a BC stem-cell marker [20], and CD24 as well as CD44 were considered CSC markers for BC as well [20,26]. In animal tumor models, interactions of CD24 with P-selectin facilitated contact of tumor cells with the vasculature [27], and CD24 seems to play an important role for metastases [28]. Another study investigated the expression of CD133 and CD24 on BC cells and concluded that a CD133\textsuperscript{pos}\textsuperscript{CD24pos} phenotype was associated with tumor progression and metastases [29]. However, CD24 as a BC stem-cell marker was questioned recently, indicating that this topic requires additional research [30]. CD44 expression was associated with homing of leukemic CSCs to their stem-cell niche [31]. Detection of CD44\textsuperscript{pos} cells may therefore be associated with CSC and stem cell niches in corresponding samples. At the same time, organ-specific CSC markers eventually open new avenues for diagnosis and therapy. In addition, analyses of the expression of these markers may facilitate the identification of CSCs in in vitro cultures as well.

In this study, we therefore investigated the expression patterns of immune checkpoint molecules PD-L1, CD276, and the immune modulatory molecule CD47 on bladder cancer organoids (BCO) in early versus late passages in comparison to the bladder cancer stem-cell markers CD24 and CD44 on protein and transcript levels. The corresponding tumor samples were characterized as well.

2. Results
2.1. Expression of Immune Checkpoint Antigens on Early and Late Passage 3D Organoids

Organoids BCO#140, #154 and #147 were established from urothelial carcinoma cells and passaged in vitro. Some key clinical data of the patients are listed in Table 1. BCO#140 yielded stable cultures expandable for more than 28 passages, which corresponded to 10 months of continued growth in vitro. BCO#154 generated cultures expandable for 20 passages, then growth decelerated. Cells of BCO#147 failed to proliferate for more than
eight passages and ceased further cell growth. The expression of immune modulatory antigens and cancer stem-cell markers was explored in early (passage 0–3) and later stages (passage 5–11). In a first set of experiments, we stained organoids in chamber slides in their three-dimensional (3D) structure to investigate the gene expression patterns of the cells in the original positions in organoids (Figures 1–3 and 7). In a second set of analyses, paraffin sections were generated from additional samples of the same organoids to compare the gene expression of individual cells in more detail (Figures 4–6 and 8).

Table 1. Information on tumor samples included.

| Patient | #140 | #147 | #154 |
|---------|------|------|------|
| Age (years) | 64 | 61 | 64 |
| Gender | male | male | male |
| Localization | bladder | renal pelvis | bladder |
| Tumor Stage (pT) | pT1 | pT4 | pT2 |
| Tumor Grade (G) | G3, high grade | G3 high grade | G3 high grade |
| Surgery | TURBT | RNU | RC |
| Histology | Small cell carcinoma | Urothelial carcinoma | Urothelial carcinoma |

1 TURBT = transurethral resection of a bladder tumor; RNU = radical nephroureterectomy, RC = radical cystectomy.

Figure 1. Expression of immune checkpoint antigens on BCO#140 organoids. Organoids of BCO#140, a population with high in vitro growth capacity, were fixed and directly stained in early passage (left panel) or in later passage (right panel) cultures with antibodies reactive with PD-L1, CD276, and CD47 as indicated. For each staining, an overview with several organoids and a detailed picture of individual organoids are presented. Size bars indicate 200 μm and 20 μm, respectively.
Figure 2. Expression of immune checkpoint antigens on BCO#154 organoids. Organoids of BCO#154, a population with moderate in vitro growth capacity, were fixed and directly stained in early passage (left panel) or in later passage (right panel) cultures with antibodies reactive with PD-L1, CD276, and CD47 as indicated. For each staining, an overview with several organoids and a detailed picture of individual organoids are presented. Size bars indicate 200 μm, 100 μm, 20 μm, and 10 μm as indicated.

Figure 3. Expression of immune checkpoint antigens on BCO#147 organoids. Organoids of BCO#147, a population with limited in vitro growth capacity, were fixed and directly stained in early passage (left panel) or in later passage (right panel) cultures with antibodies reactive with PD-L1, CD276, and CD47 as indicated. For each staining, an overview with several organoids and a detailed picture of individual organoids are presented. Size bars indicate 200 μm and 20 μm, respectively.
Figure 4. Expression of immune checkpoint antigens on BCO#140. Paraffin sections of organoids of BCO#140, a population with high in vitro growth capacity, were generated and stained in early passage (left panel) or in later passage (right panel) with antibodies reactive with PD-L1, CD276, and CD47 as indicated. In the bottom panel, CD47 is visualized by red fluorescence, CD276 by green fluorescence. Size bars indicate 20 μm, respectively.

Figure 5. Expression of immune checkpoint antigens on BCO#154. Paraffin sections of organoids of BCO#154, a population with moderate in vitro growth capacity, were generated and stained in early passage (left panel) or in later passage (right panel) with antibodies reactive with PD-L1, CD276, and CD47 as indicated. In the bottom panel, CD47 is visualized by red fluorescence, CD276 by green fluorescence. Size bars indicate 20 μm, respectively.
Expression of immune regulatory antigens on bladder cancer organoids in chamber slides has revealed distinct expression patterns among different populations. 

In early passage organoids in chamber slides, CD276 was detected in more than 70% of the cells, while PD-L1 was not detected or expressed only on a few cells. The majority of cells expressed CD47 (Figures 1–3; Table 2). In late passage organoids, comparable expression patterns were observed (Figures 1–3; Table 2). Differences in the expression patterns of immune modulatory antigens among the stable and expandable BCO#140 in comparison to the less-stable BCOs were not observed. Detailed antigen staining patterns of representative organoids are presented online (Supplementary Materials).

### Table 2. Expression of immune regulatory antigens on bladder cancer organoids in chamber slides

| Cell     | Passage | PD-L1 | CD 276 | CD 47 |
|----------|---------|-------|--------|-------|
| BCO#140  | Early   | +     | 3+     | 3+    |
|          | Late    | +/−   | 3+     | 3+    |
| BCO#154  | Early   | +/−   | 3+     | 3+    |
|          | Late    | +/−   | 3+     | 3+    |
| BCO#147  | Early   | −     | 3+     | 3+    |
|          | Late    | +/−   | 3+     | 3+    |

The expression ratio of antigens in early (P ≤ 3) and late (P ≥ 5) passage organoids was counted by fluorescence microscopy. The percentage of positive cells were scored as follows: +/−: < 5%, +: 5~30%, 2+: 30~70%, 3+: >70% of total cells. Total numbers of cells were visualized by DAPI and counted accordingly.

To explore the expression of the immune checkpoint antigens and immune modulatory CD47 on an individual cellular level and in more detail, paraffine sections were generated. CD276 and CD47 were found to be prominently expressed in the cells of BCO#140, #147, and #154 (Figures 4–6, Table 3). The expression patterns of the immune checkpoint molecule CD276 and the “do-not-eat-me signal” CD47 presented remarkable patterns. In BCO#140, CD276+ and CD47+ cells were distributed randomly in the organoids (Figures 4 and 5). Only a few double-positive cells were noted in early and late passage cells. BCO#140 and BCO#154 were clusters filled with cells. By contrast, urothelial carcinoma cells of patient #147 generated mainly hollow spheroids (Figure 6). At least in the early-stage organoids, a distinct expression pattern of CD47 and CD276 was noted. On the same cell, CD276 was...
found on the outside of the organoid, while CD47 was found in the inside. This polarity became visible as in early stages the BCO#147 spheres grew in large part as monolayers (Figure 6). This pattern was maintained to some degree through later stages on spheres.

Table 3. Expression of immune regulatory antigens in paraffin sections of bladder cancer organoids.

| Cell   | Passage | PD-L1 | CD 276 | CD 47 |
|--------|---------|-------|--------|-------|
| BCO#140| Early   | pos   | pos    | pos   |
|        | Late    | pos   | pos    | pos   |
| BCO#154| Early   | pos   | pos    | pos   |
|        | Late    | neg   | pos    | pos   |
| BCO#147| Early   | neg   | pos    | pos   |
|        | Late    | pos   | pos    | pos   |

The expression ratio of antigens from early (P ≤ 3) and late (P ≥ 5) passages of organoids. Due to the method applied, the expressions of factors investigated are described as positive (pos) versus negative (neg) but not quantified by any means.

2.2. Expression of Bladder Cancer Stem-Cell Markers CD24 and CD44 on Early and Late Passage 3D Organoids

The expression of bladder cancer stem-cell markers CD24 and CD44 was investigated on organoids as well. While the expression of CD44 was observed in all three organoids, in early and later stages of in vitro culture, the expression of CD24 was remarkably different (Figure 7, Table 4). BCO#140 presented a prominent signal of CD24 in early-stage cultures, and even in later passages, some cells expressed CD24 (Figure 7). Only a few CD24⁺/CD44⁺ double-positive (DP) cells, visualized by yellow fluorescence, were found. Overall, the red fluorescent CD44⁺ cells were enriched in an outer ring while the green fluorescent CD24⁺ cells were found in an inner ring, separated partly by a layer of CD24⁻/CD44⁻ double-negative (DN) cells (Figure 7).
Figure 7. Expression of CD24 and CD44 on organoids. Organoids of BCO#140, #154, and #147 were fixed and stained with primary antibodies reactive with bladder cancer stem-cell markers CD24 and CD44. Expression of CD24 was visualized by a green fluorescent AlexaFluor488-labelled detection antibody. CD44 was visualized by a red fluorescent Cy3-labelled detection antibody. Cell nuclei were stained by DAPI.

Table 4. Expression of stem-cell markers on organoids of BC in chamber slides.

| Cell   | Passage | CD 24 | CD 44 |
|--------|---------|-------|-------|
| BCO#140 | Early   | 2+    | 3+    |
| BCO#140 | Late    | 2+    | 3+    |
| BCO#154 | Early   | +     | 3+    |
| BCO#154 | Late    | −     | 3+    |
| BCO#147 | Early   | −     | 3+    |
| BCO#147 | Late    | −     | 3+    |

The expression ratio of antigens in early (P ≤ 3) and late (P ≥ 5) passage organoids was counted by fluorescence microscopy. The percentage of positive cells was scored as follows: +/−: < 5%, +: 5~30%, 2+: 30~70%, 3+: >70% of total cells. Total numbers of cells were visualized by DAPI and counted accordingly.

In contrast, in BCO#154, only a few cells expressed CD24 in early-stage cultures. As seen in BCO#140, CD24+ cells were not found frequently in the outer zone of the organoid but enriched in the center (Figure 7). On BCO#154, CD24+ /CD44+ DP urothelial carcinoma cells were not detected (Figure 7). Moreover, in later-stage BCO#154, expression of CD24 ceased, but the organoids maintained a prominent expression of CD44 (Figure 7, Table 2). The cells in BCO#147 failed to express CD24 even in early passages but expressed CD44 in early- as well as in later-stage cultures (Figure 4, Table 3).

The analysis of expression of CD24 and CD44 in paraffin sections of the same organoids yielded somewhat different results (Figure 8). As described above, prominent expression of CD24 was observed on BCO#140 and BCO#154 in early-stage and later-stage cultures. In BCO#147 samples, CD24 was not detected. CD44 was detected in all samples (Figure 8, Table 4). Overall, this corroborated that BCO#147 was not enriched for cells expressing stem-cell-marker CD24, and this correlated with moderate expansion capacities of organoids from this donor, while BCO#140 and BCO#154 expressed CD24, and this correlated with an
extended expansion capacity (Tables 4 and 5). Of note, BCO#147 generated hollow spheres, which was not observed in BCO#140 and BCO#154 (Figure 8).

Table 5. Expression of stem-cell markers in paraffin sections of BC organoids.

| Cell     | Passage | CD 24 | CD 44 |
|----------|---------|-------|-------|
| BCO#140  | Early   | pos   | pos   |
|          | Late    | pos   | pos   |
| BCO#154  | Early   | pos   | pos   |
|          | Late    | pos   | pos   |
| BCO#147  | Early   | neg   | pos   |
|          | Late    | neg   | pos   |

The expression ratio of antigens from early ($P \leq 3$) and late ($P \geq 5$) passages of organoids. Due to the method applied, the expressions of factors investigated are described as positive (pos) versus negative (neg) but not quantified by any means.

2.3. Transcripts Encoding the Immune Modulatory Factors and Stem-Cell Markers

In addition, we investigated the expression of the immune modulatory cell surface proteins and stem-cell markers on the transcript levels on BCOs. Early-passage (HL19/16) and late-passage (Hblac) normal human urothelial cells served as controls (Figure 9). Transcripts encoding PD-L1, CD276, and CD47 were detected in the normal urothelial cells and in BCOs in all samples investigated, and only minor differences were computed (Figure 9). The expression of BC stem-cell markers CD24 and CD44 was investigated on transcript levels as well (Figure 9). A reduced expression of CD24 was noted in late-stage normal urothelial cells when compared to early-stage urothelial cells (Figure 9). A comparable trend was observed in BCO#140 and BCO#154 organoids in early versus late cultures. Most importantly, the highest expression of CD24 transcripts was determined in early-stage BCO#140 (Figure 9). Of note, BCO#147 expressed CD24 transcripts in the later passage, although protein expression was not detected on cultured cells or paraffin sections of organoids (Figures 7 and 8). In general, transcripts encoding CD44 were slightly below CD24. In late-passage normal cells, the trend of reduced expression of CD44 was observed, while in early versus late BCO#140 and BCO#154, no differences were found (Figure 9).
expression of CD24 was observed on BCO#140 and BCO#154 in early-stage and later-stage cultures. In BCO#147 samples, CD24 was not detected. CD44 was detected in all samples (Figure 8, Table 4). Overall, this corroborated that BCO#147 was not enriched for cells expressing stem-cell-marker CD24, and this correlated with moderate expansion capacities of organoids from this donor, while BCO#140 and BCO#154 expressed CD24, and this correlated with an extended expansion capacity (Tables 4, 5). Of note, BCO#147 generated hollow spheres, which was not observed in BCO#140 and BCO#154 (Figure 8).

Figure 8. Detection of CD24 and CD44 on paraffin section of organoids. Paraffin sections of BCO#140, #154, and #147 were generated and stained with primary antibodies reactive with bladder cancer stem-cell markers CD24 and CD44. Expression of CD24 was visualized by a green fluorescent AlexaFluor488-labelled detection antibody. CD44 was visualized by a red fluorescent Cy3-labelled detection antibody. Cell nuclei were stained by DAPI.

Table 5. Expression of stem-cell markers in paraffin sections of BC organoids.

| Cell     | Passage | CD24 | CD44 |
|----------|---------|------|------|
| BCO#140  | Early   | pos  | pos  |
|          | Late    | pos  | pos  |
| BCO#154  | Early   | pos  | pos  |
|          | Late    | pos  | pos  |
| BCO#147  | Early   | neg  | pos  |
|          | Late    | neg  | pos  |

The expression ratio of antigens from early (P ≤ 3) and late (P ≥ 5) passages of organoids. Due to the method applied, the expressions of factors investigated are described as positive (pos) versus negative (neg) but not quantified by any means.

2.3. Transcripts Encoding the Immune Modulatory Factors and Stem-Cell Markers

In addition, we investigated the expression of the immune modulatory cell surface proteins and stem-cell markers on the transcript levels on BCOs. Early-passage (HL19/16) and late-passage (Hblac) normal human urothelial cells served as controls (Figure 9). Transcripts encoding PD-L1, CD276, and CD47 were detected in the normal urothelial cells and in BCOs in all samples investigated, and only minor differences were computed (Figure 9). The expression of BC stem-cell markers CD24 and CD44 was investigated on transcript levels as well (Figure 9). A reduced expression of CD24 was noted in late-stage normal urothelial cells when compared to early-stage urothelial cells (Figure 9). A comparable trend was observed in BCO#140 and BCO#154 organoids in early versus late cultures. Most importantly, the highest expression of CD24 transcripts was determined in early-stage BCO#140 (Figure 9). Of note, BCO#147 expressed CD24 transcripts in the later passage, although protein expression was not detected on cultured cells or parafin sections of organoids (Figures 7 and 8). In general, transcripts encoding CD44 were slightly below CD24. In late-passage normal cells, the trend of reduced expression of CD44 was observed, while in early versus late BCO#140 and BCO#154, no differences were found (Figure 9).

Figure 9. Enumeration of transcripts encoding immune modulatory antigens and stem-cell markers.

RNA was extracted from organoids of BCO#140, #154, and #147 in early (plain bars) and late (dashed bars) passages as indicated to generate cDNA for quantitative PCR. Human urothelial cells HL19/16 and Hblac served as normal early- and late-passage controls, respectively. The y-axis presents the transcript amounts normalized to two house-keeping genes; the x-axis shows the target gene investigated as indicated.
2.4. Expression Marker Proteins on Tissue Samples of the Corresponding Bladder Cancer

The expression of the immune modulatory antigens and the stem-cell markers were investigated in the corresponding ex vivo tumor samples of patients #140, #154, and #147 as well (Figure 10). The expression of PD-1 and PD-L1 was observed by immunohistochemistry only on a few cells of BC tissue samples, but a prominent signal was observed for CTLA-4 (Figure 10). In all paraffin sections investigated, some cells expressed CD276, but only weak signals were observed for CD47 expression in one of three bladder-cancer samples (Figure 10). The expression of stem-cell markers CD24 and CD44 staining was seen only in a few individual cells, but not in considerable areas of the samples (Figure 10).

![Immune Checkpoint Antigens and Stem-Cell Markers in Bladder Cancer Tissue](image)

**Figure 10.** Detection of immune checkpoint antigens and stem-cell markers in bladder cancer tissue.

To correlate the expression patterns observed by organoids in vitro with the pathological situation in bladder cancer tissue, paraffin sections were stained with antibodies to PD-1, PD-L1, CTLA-4, CD276, CD47, CD24, and CD44 as indicated, and detected by immunohistochemistry. Tissues were counter-stained by HE. Size bars indicate 100 μm.
3. Discussion

In this study, we investigated the expression of immune modulatory antigens and CSC markers CD24 and CD44 on BCOs in early and late passages. More than 30 years ago, CD24, then termed NALM-6M1, was described as a cell-surface molecule on pre-B-lymphocytes, and transcripts were found to be enriched in tumor cells which carried functional mutations of tumor suppressor gene p53 [32,33]. CD24 is a small adhesion molecule (80 amino acids, 8082 Dalton molecular mass). It was shown to promote the invasion of tumor cells [34]. CD24 is highly expressed on bladder cancer samples, and it was associated with tumor cell proliferation, the potential of colony-forming units in soft agar cultures, and the regulation of apoptosis [35,36]. Analysis of clinical data provided evidence that the expression of CD24 correlated significantly with a rather short remission-free survival of the patients and an increased risk of metastases [28,35]. These data are in line with our results, as elevated expression of CD24 in early- and later-stage organoids was evident in the long proliferating BCO#140 cells, but not detectable in line BCO#147 on protein levels in both early- as well as late-passage organoids. In addition, the highest transcript levels encoding CD24 were enumerated in early-stage BCO#140 cells, correlating to its relevance for organoid stability in vitro. The mechanisms involved in higher BCO stability may include the effects of CD24 on cell–matrix interactions [37]. In cell-attachment assays, CD24 facilitated cell binding to fibronectin, to collagens I and IV, and to laminins through α3β1 and α4β1 integrins [38]. Matrigel—employed to generate the organoids in this study—is prepared from murine sarcoma supernatants and contains about 60% laminins, 30% collagen IV, and some other components. CD24high urothelial carcinoma cells may therefore attach better to this scaffold when compared to CD24low cells [38]. Integrin binding to the extracellular matrix may modulate pro-apoptotic signals [39]. Integrin signaling may even reduce the sensitivity of cancer cells to apoptosis-inducing chemicals [40,41]. However, in pancreatic cancer cells, low expression of CD24 correlated with augmented adhesion to Matrigel, while elevated CD24 correlated with reduced adhesion [42]. This suggests that the attachment of CD24high bladder cancer cells to the extracellular matrix in organoids may depend not only on β1 integrin-mediated binding but possibly also on additional factors.

Insufficient cell binding of adherently growing cells such as epithelial cells in spheroids is associated with apoptosis [43]. This may explain the instability of organoids by increased loss of CD24high cells in the organoids. Moreover, CD24 was described as a mucin-like adhesion molecule, specifically binding to P-selectin, but not to E- or L-selectins [37]. Therefore, CD24 may contribute to direct cell-to-cell binding in organoids. However, the expression of P-selectin (CD62P) was not observed in normal bladder tissue [44], but elevated soluble P-selectin was found in the serum of bladder cancer patients [45]. As serum from patients is not complementing our cell culture media, P-selectin seems not to be critical for actions of CD24 on BCO stability and growth discussed here. Cross-linking CD24 induces apoptosis in a variety of cells [46,47]. However, this requires a corresponding cross-linking ligand and therefore probably does not play a role in our experimental setup. Taken together, we conclude that CD24high bladder cancer cells are protected in organoids from CD24-induced apoptosis as urothelial cells express the CD24-ligand P-selectin at low levels, while at the same time elevated soluble P-selectin in the serum of bladder cancer patients prevents CD24 cross-linking on the tumor cells, and at the same time apoptosis of CD24high cells in tumor tissues.

We noted that the CD24 transcript levels in late-stage normal urothelial cells Hblac were clearly lower when compared to less expanded normal urothelial cells HL19/16. The same trend was observed in BCO#140 and BCO#154 cells. Although transcripts encoding CD24 were detected in all late stage BCOs investigated, our results suggest that expression of the CD24 depends on culture time or number of passages of BCOs in vitro. This finding is corroborated by studies employing serial cell expansions to investigate the number of CD24pos cells [48]. Moreover, experimental knock-down of CD24 expression in human bladder cancer cell lines reduced sphere formation, sensitivity to cisplatin-induced apoptosis, reduced the expression of the tumor stem-cell marker CD133, and attenuated
tumor growth in an in vivo cancer model [26]. An invasive phenotype was associated in BC with CD133posCD24pos co-expression [29]. In contrast, in mesenchymal breast cancer-derived cell lines the invasive phenotype was associated with a CD44posCD24neg phenotype [49]. This conflict of data may be resolved by the hypothesis that CD24high cells in our organoids are epithelial/urothelial cells but not mesenchymal cells based on their expression of cytokeratins [50]. In addition, expression of CD24 on urothelial carcinoma is androgen regulated [51]. A loss of CD24 expression on BCOs over time of in vitro expansion may be associated with a reduced level of androgen signaling through androgen receptors [51]. As both BCO#140 and BCO#147 were derived from male donors, major differences in androgen signaling are not expected. Detailed experiments along these lines on larger cohorts including BC samples from male and female donors must be addressed in future studies. Taken together, elevated expression of CD24 may serve as indicator for promising expansion of bladder cancer organoids.

The role of CD44 in the context of BC stem-cell markers seems less clear [20,52] and an androgen regulation was suggested [53]. We confirm the expression of CD44 on BCOs on transcript and protein levels in early and later passages and in situ in BC tissue samples. Recent animal studies corroborated a low expression of CD44 on 3D bladder cancer organoids, which was upregulated by propagation of the cells in so-called 2.5D organoid constructs in later passages [14,54,55]. We assume that the role of CD44 in BCOs requires further investigations.

Other results also merit discussion. By immunohistochemistry, we detected expression of PD-1 and CTLA-4 on paraffin sections of tumor samples. PD-1 and CTLA-4 are considered immune checkpoint molecules on T lymphocytes [56]. Proliferation of T cells requires IL-2. However, this cytokine is not added to our BCO expansion medium. Accordingly, by RT-qPCR, PD-1 transcripts were not detected at all or recorded at the detection threshold (data not shown). In contrast, CTLA-4 staining was prominent in all tumor samples investigated. This indicated that CTLA-4 pos cells were enriched in bladder cancer tissue. In the BCOs, CTLA-4 transcripts were barely above the detection threshold of this technique and two logs below the transcript amounts recorded for PD-L1 (data not shown). This result was unexpected as CTLA-4 is a well-known T lymphocyte antigen. However, recently it was shown that CTLA-4 can be expressed on thymic epithelial cells upon functional loss of the autoimmune regulator AIRE [57]. We therefore cannot exclude that some BCO cells transcribed mRNA encoding this T-lymphocyte associated gene. However, this remains to be investigated in future experiments.

Due to the sensitive technology employed for immunofluorescence, the signal intensities shown in this study should not be interpreted as quantitative data in the sense of describing expression levels or protein amounts in or on individual cell. Comparably, the staining patterns presented in the tables should also not be interpreted as indicators for staining intensities in or on individual cells in organoids, but strictly taken as indicator of the percentage of cells showing in staining. This challenge in data interpretation becomes evident when staining patterns of whole organoids in 3D structures are compared to the patterns obtained from the same organoids and passage by paraffin sections. One has to take into account that staining of whole organoids in 3D may detect primarily proteins on cell surfaces, while on paraffin sections, antibodies bind to both intracellular antigens and membrane-bound targets. Moreover, in organoids, fluorescence from the whole construct may add up to a collective staining. In contrast, in thin paraffin sections, less antigen mass is accessible. These differences may contribute to the different signal frequencies observed between 3D organoid staining in comparison to staining of paraffin sections. However, investigating BCOs by fluorescence microscopy in their 3D structure as well as in paraffine sections provided another advantage as well. The hollow structure of BCO#147 was clearly demonstrated in paraffine sections, but it was not evident from immunofluorescence analyses of organoids in 3D. Some difference between BCO#140 and BCO#154 and BCO#147 were also observed for expression of BC stem-cell marker CD24 in the three BCOs investigated here.
While most BCO studies published to date investigated the expression of cytokeratins, proliferation, and tumor markers in vitro in comparison to the tumor in vivo [58–60], information of the dynamics of expression of immune checkpoint antigens on BCOs is more limited. However, such data may become a valuable tool to screen for patient-specific checkpoint therapies when the regulation of these cell surface proteins is explored in more detail. At present, we continue to investigate these differences between staining of whole organoids and the corresponding paraffin sections with the transcript levels. In addition, we complement these studies by immunohistochemistry of cryosections.

One of the limitations of this study is the low number of individual BCOs investigated at the time of exploration. We intended to study the expression of immune checkpoint antigens and bladder cancer stem-cell markers in BCOs in early as well as late passages. Sufficient material was available from many tumor samples. Cells from many BC tissue samples were seeded in Matrigel. However, after initial growth, some samples failed to generate three-dimensional constructs resembling bona fide BCOs but rather grew in cellular clusters with fuzzy rim and without convincing mitotic activity. In addition, several BCOs retarded proliferation in passages 3 to 5. Only a few passed this crisis, including BCO#140, BCO#147, and BCO#154. Other BCOs passed beyond passage 5 but did not provide sufficient material for molecular analyses at later stages. To overcome these limitations in the future, we investigated all possibilities to improve the efficacies of BCO production and long-term culture. Moreover, only surgical samples from male tumor patients were included. In future studies, tumor samples from female patients and from patients representing clinical pTa to pT4 BC tumors should be included.

Bladder cancer-derived organoids have been and will be part of intensive research in tumor biology [58,59,61,62]. They reflect the tumor situation much better when compared to standard 2D cultures and may even help to better comply with refinement, reduction, and even in part replacement of studies employing living animals in pre-clinical tumor research. We recently initiated experiments to use organoids to investigate in vitro some of the physical and chemical characteristics of BC and to facilitate the discrimination between normal and malignant bladder tissue [63].

4. Materials and Methods

4.1. Bladder Cancer Organoids

Pathologist confirmed urothelial carcinoma samples were obtained from patients undergoing surgery after written and informed consent. The study was approved by the local Ethics Committee under file number 804/2020/B02. Tumor cells were isolated from the tissue by mechanical degradation followed by proteolytic digest and seeded in hydrogel domes as described recently [59]. In brief, the tissue was minced and collected by centrifugation (480 g, 10 min. ambient temperature (a.t.)). The sediment was resuspended in buffer containing collagenase (3000 U/mL) and hyaluronidase (1000 U/mL), and incubated under moderate agitation (37 °C, 30 min). The proteolytic degradation was continued by adding fresh collagenase for 30 min at 37 °C. Debris was removed by a cell strainer (70 µm mesh) and the filtrate was sedimented by centrifugation (150 g, 7 min, a.t.). The yield and viability of the cells were enumerated, resuspended at 4E06/mL to obtain 4E04 cells in 10 µL. These cells were mixed on ice with 30 µL Matrigel, dipped in a 24-well plate and flipped upside-down to generate hanging drops. After a short incubation at 37 °C, the plates were turned back, complemented with 500 µL BTM culture medium per well, and incubated in a cell-culture incubator (37 °C, 5% CO2, humidified atmosphere). All organoid cultures included in this study were downscaled to match 48-well plates. Normal human urothelial cells HL19/16 in early passage and commercial urothelial cells in late passage (Hblac, CELLnTEC) served as controls [64]. A detailed protocol is disclosed in Appendix A.

4.2. Immunofluorescence and Immunohistochemistry

To characterize the BC organoids, two distinct methods of immunofluorescence were applied. For three-dimensional evaluation of the BCOs, organoids were cultured in 8-well
chamber slides. Immediately prior to staining, the medium was aspirated and the BCOs were fixed by 4% formaldehyde (30 min, a.t.), washed well three times with PBS, blocked (5% BSA, 0.2% Triton X-100, 0.1% Tween 20, in PBS; 1 h, a.t.), and incubated (1 h, 37 °C, humidified chamber, dark) with primary antibodies to immune checkpoint antigens PD-L1, CD276, to immunoregulatory molecule CD47, as well as to bladder cancer stem-cell markers CD24 and CD44. Unbound primary antibodies were washed away (3 × 5 min, PBS, a.t.). Primary antibodies were detected by incubation of the samples with complementary fluorescence-labelled secondary antibodies (1 h, a.t., humidified chamber, dark). Unbound secondary antibodies were rinsed away (3 × 5 min., PBS, a.t.). Cellular nuclei were counterstained by DAPI, and the expression of the marker genes was visualized by microscopy (Leica Stellaris 8 or Zeiss Axiophot). Antibody diluent was 1% BSA in PBS. Samples omitting the primary antibodies and samples stained with mouse or rabbit IgG isotype antibodies served as controls (data not shown). Details on the antibodies employed are listed in Appendix B.

For two-dimensional analyses of BCO paraffin, sections were generated following standard procedures. BCOs were expanded in 48-well plates to reach the culture density desired. The medium was aspirated and BCOs were rinsed twice by PBS and fixed (4% formaldehyde, overnight (o.n.), a.t.). The BCOs were dehydrated and embedded in paraffin. Paraffin sections were generated (3 µm, Leica RM2125, a.t.), dewaxed and rehydrated by aid of incubation in xylene, rehydrated by ethanol in decreasing concentrations, and mounted on glass slides as described [65]. The samples were incubated with the primary and secondary antibodies as described above. Cellular nuclei were counterstained by DAPI, and the expression of the marker genes was visualized by microscopy (Zeiss Axiophot). Samples omitting the primary antibodies and samples stained with mouse or rabbit IgG isotype antibodies served as controls (data not shown). Details on the antibodies employed are listed in Appendix B.

Immunohistochemistry of paraffin sections was utilized to detect expression of the immune modulatory antigens and bladder cancer stem-cell markers in bladder cancer tissue samples from the patients corresponding to #140, #154, and #147. In addition to the organoid samples, tumor samples were stained with antibodies to PD-1 and CTLA-4 (Appendix B). The primary antibodies were washed off (3 × for 5 min, PBS), and detected by the HRP or AP polymer reagent (IHC ZytochemPlus) The samples were counterstained by HE, covered (VectaMount, Vectorlabs), and recorded by microscopy (Axiovert A1, Zeiss).

4.3. Transcript Analyses

Quantification of gene expression on mRNA transcript levels was performed as described [66]. In brief, the cells were washed and counted. Nucleic acids were extracted, DNA was degraded enzymatically, and total RNA was isolated using a kit (RNeasy, Qiagen, Hilden, Germany). The yield and purity of total RNA were determined by UV spectroscopy (Nanodrop; Implen, Munch, Germany). A measure of 1 µg of total RNA was reverse transcribed employing oligo-(dT) primers (Advantage RT-for-PCR kit TakaraBio, Saint-Germain-en-Laye, France). Quantitative PCR (LightCycler 480; Roche, Pensberg, Germany) of cDNA corresponding to the target genes was performed as described recently [67]. The primer sequences are listed in Appendix C. Quantification of transcripts encoding GAPDH and β-actin served as controls, and amounts of target transcripts were normalized in each batch to the two controls as described [67].

5. Conclusions

We conclude that elevated expression of CD24 on bladder cancer organoids may serve as an indicator for the in vitro culture and expansion capacities of BCOs. This notion is supported by our results on transcript and protein levels. Studies to investigate the diagnostic and therapeutic potential of CD47 and CD276 by aid of BCOs seem feasible, while the expression patterns observed for CTLA-4 on BCOs require additional research.
Using three distinct BCOs is the limitation of our experiments. The study will therefore be complemented by additional research.

**Supplementary Materials:** The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/ijms23105453/s1.

**Author Contributions:** Conceptualization: N.H., W.K.A., A.S. and B.A.; technology, investigation: R.G., I.A.M.-M. and F.F.; writing, review and editing, all authors; funding acquisition: W.K.A., A.S. and F.F. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research was funded in part by grants of the Deutsche Forschungsgemeinschaft GRK2543 (#663952 to A.S. and F.F.), PoTuS (#29049495 to W.K.A., A.S., and B.A.), and in part by institutional funding.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** The study was performed after informed and written consent of all subjects involved. The protocol was approved by the local Ethics Committee under file number 804/2020/B02.

**Data Availability Statement:** Data will be provided to colleagues in public research institutions upon specific request.

**Acknowledgments:** The authors express their great gratitude to Tanja Abruzzese and Conny Bock for excellent technical support, Viktoria Kramer-Potapenja for critically revising the manuscript, and to Chaim Goziga for preparing the artwork. Open access publication was supported by University of Tuebingen funds.

**Conflicts of Interest:** The authors declare no conflict of interest for this study.

**Abbreviations**

- a.t. ambient temperature
- BC bladder cancer
- BCO bladder cancer organoids
- BSA bovine serum albumin
- CSC cancer stem cell(s)
- DN double negative
- DP double positive
- IMA immune modulatory antigen(s)
- f.c. final concentration
- o.n. overnight

**Appendix A**

**Appendix A1. Isolation of Cells**

**Materials required**

- **BCO culture medium:** Bladder Tumor cell Medium (BTM) complemented by supranatant from L-R cells expanded with 5% charcoal-stripped FBS
- **Working medium:** DMEM, enriched by 2 mM L-Glutamine, 10% FBS, 1% pen/strep, 100 mM Y-27632 (MedChem Express, Monmouth Junction, NJ, USA)
- Collagenase/Hyaluronidase (10×, Stem Cell Technologies, Vancouver, BC, Canada): 3000 U/mL collagenase; 1000 U/mL hyaluronidase;
- **RBC Lysis Buffer** (Invitrogen eBioscience, San Diego, CA, USA)
- Matrigel (BME, BioTechnne, Minneapolis, MN, USA) thaw it on wet ice, mix well and keep on wet ice)
- Dulbecco’s PBS (DPBS)
- Wet ice
- Cell strainer 70 µm
- Tissue culture Petri dish PS 15/60 mm
- 48-well plate, preheated at 37 °C in the incubator
15 mL centrifugation tube
50 mL centrifugation tube
1.4 mL microcentrifugation tube

Procedure:
- Prewarm media and PBS to 37 °C, prewarm collagenase/hyaluronidase to a.t.
- Check weight of petri dish
- Transfer the piece of tissue to the Petri dish: Remove the transport medium, aspirate the tissue with a pipette and place it in the Petri dish—aspirate the excess medium—put the lid on the Petri dish and weigh the tissue
- Pour 1 mL of the working medium into the Petri dish
- Cut the tissue into approx. 1 mm pieces by aid of 2 sterile scalpels
- Resuspend the minced tissue in 5 mL working medium and transfer minced tissue in a 15 mL tube using a pipette. Rinse the Petri dish with fresh working medium and transfer it to the 15 mL tube as well
- Centrifugation at 480 × g, 10 min, a.t., aspirate the supernatant
- Resuspend the pellet in DPBS using 1000 µL DPBS per 100 mg wet weight of tissue
- Add 15 µL collagenase / hyaluronidase per 1000 µL DPBS or 100 mg tissue to the 15 mL tube
- Place the tube in the incubator (37 °C, 5% CO₂, 30 min) and take it out in between and mix gently
- After 30 min, add the same amount of collagenase/hyaluronidase to the 15 mL tube and incubate for additional 30 min under the same conditions, occasionally mix the samples
- Filter digested tissue through a 70 µm cell strainer into a 50 mL tube. If the sieve is clogged, filter the residual material with a new sieve (2–3 times if necessary). Rinse clogged filters with DPBS if needed.
- Collect filtrates in a 15 mL tube
- Centrifugation 150 g, 7 min, a.t., aspirate the supernatant, leave approx. 200 µL pellet and suspension in the tube
- Add 10 mL RBC Lysis Buffer, incubate 10 min on ice
- Centrifugation 150 g, 7 min, a.t., aspirate the supernatant
- Resuspend the cell pellet in 1000 µL working medium
- Mix but well by gentle pipetting, transfer an aliquot (10 µL) into a 96-well plate to determine the yield and viability of cells by trypan blue by exclusion in a Neubauer counting chamber
- Dilute the samples to the cell density of 2 × 10⁶ cells/mL, corresponding to 10,000 cells/dome, put diluted cells on wet ice
- Calculate the required amount of Matrigel (15 µL BME per 5 µL cell suspension and well).
- Mix 5 µL per well of cell suspension with 15 mL of cold Matrigel. Avoid air bubbles
- Collect the 48-well plate from the incubator, immediately plate out Matrigel domes (20 µL/dome)
- Turn over the plate and place it up-side down in a cell culture incubator (37 °C, 5% CO₂, humidified atmosphere) for 45 min
- Collect the plate and turn it over again. Tilt the plate slightly, slowly pipette 250 µL of BCO culture medium into the lower edge
- Incubate the dome at 37 °C, 5% CO₂, humidified atmosphere in a cell culture incubator

Appendix A2. Splitting of Organoids

Materials required:
BCO culture medium
Dispase II: Sigma-Aldrich (St. Louis, MN, USA), 2 mg/mL in Advanced DMEM/F-12
TrypLE Express: Gibco—Thermo Fisher—Gibco (Waltham, MA, USA) without phenol red
Matrigel (BME BioTechne, Minneapolis, MN, USA)
48 well plates
1.4 mL centrifugation tubes
15 mL centrifugation tubes
Wet ice

**Stop medium:** Advanced DMEM/F-12, 10% FCS, 1% pen/strep, 1 µL/10 mL 100 mM Y-27632 (MedChem Express, Monmouth Junction, NJ, USA)

**Procedure:**
- Carefully aspirate BCO culture medium, avoid destruction/removal of organoids
- Add 250 µL DPBS + 50 µL Dispase II per well, incubate 60 min in a cell culture incubator (37 °C, 5% CO₂, humidified atmosphere)
- Add 200 µL TrypLE by pipette, resuspend carefully and transfer the suspension in 1.4 mL centrifugation tube
- Digest the Matrigel scaffold by incubation on a rotating shaker for exactly 15 min at 37 °C and 1400 rpm
- Resuspend the sample well by gentle pipetting, transfer in to a 15 mL tube and add 1 mL of stop medium.
- Centrifugation (150 g, 7 min, a.t.), then carefully remove the supernatant. Add BCO culture medium to split the cultures in new domes.

**Appendix B**

**Table A1.** Antibodies employed for chamber slides (C.S.) and paraffin sections (P.S.).

| Antibody          | Isotype | Host      | Dilution (C.S.) | Dilution (P.S.) | Company     | Catalog Number |
|-------------------|---------|-----------|-----------------|-----------------|-------------|---------------|
| Anti–PD–L1        | Ig      | Mouse     | 1:100           | 1:50            | Sigma       | SAB3500122    |
| Anti–PD–L1        | IgG1k   | Mouse     | 1:50            | 1:50            | Invitrogen  | 14–5983–82   |
| Anti–CD 276       | IgG     | Rabbit    | 1:100           | 1:50            | Abcam       | Ab226256     |
| Anti–CTLA–4       | IgG2α Kappa | Mouse | 1:100          | 1:50            | Abnova      | H0001493-M08 |
| Anti–CD 47        | IgG     | Mouse     | 1:50            | 1:50            | Invitrogen  | 14–0479–82   |
| Anti–CD 24        | IgG     | Rabbit    | 1:50            | 1:50            | Abcam       | Ab20073      |
| Anti–CD 44        | IgG     | Mouse     | 1:100           | 1:50            | Abcam       | Ab9524       |
| Isotype control IgG | IgG     | Rabbit    | 1:100           | 1:50            | Abcam       | Ab172730     |
| Isotype control IgG | IgG     | Mouse     | 1:100           | 1:50            | Abcam       | Ab281291     |
| DAPI              | IgG (H + L) | Goat anti–rabbit | 1:1000          | 1:1000         | Jackson Imm.Res. | 111 – 545 – 045 |
| Alexa Fluor®488   | IgG (H + L) | Goat anti–rabbit | 1:1000          | 1:1000         | Jackson Imm.Res. | 15 – 165 – 166 |

**Appendix C**

**Table A2.** Primer sequences.

| Primer | Product Size (bp) | Forward | Reverse | Citation |
|--------|-------------------|---------|---------|----------|
| PD–L1  | 204               | GTACCTTGCGTTTGCCCAT    | CCAACACCAACAGGAGGAGT   | Primer–BLAST         |
| CD 276 | 224               | TTTCCTTCTCCCTCTCCCTCC  | TGTGACCAGCAGATCTCTCC   | Primer–BLAST         |
| CD 47  | 213               | GGAGCCATCTTCTTTGCTCCA  | ACAGCGCGCATAACAGAGAC   | Primer–BLAST         |
| CD 24  | 208               | TGAAGAACATGTGAGGTTGAC  | GAAAAACTGAATCTCCACTTCCAACAA  | Primer–BLAST         |
| CD 44  | 377               | CACAATCCAGGCAACTCCTA   | TACTCTGCTGCTGCTCATT    | Primer–BLAST         |
| GAPDH  | 346               | GCTTCTCCAGAAGCTCATCCTGCC | CGTGTTCAATCCAGAATAGGCTT   | Primer–BLAST         |
| β–actin| 276               | AACTGGAGCGACATGAGGAGA  | AATCCCCATGATGACAGGA   | Primer–BLAST         |

**References**

1. Van Rhijn, B.W.; Burger, M.; Lotan, Y.; Solsona, E.; Stief, C.G.; Sylvester, R.J.; Witjes, J.A.; Zlotta, A.R. Recurrence and progression of disease in non-muscle-invasive bladder cancer: From epidemiology to treatment strategy. *Eur. Urol.* 2009, 56, 430–442. [CrossRef] [PubMed]
2. Richters, A.; Aben, K.K.H.; Kiemeney, L. The global burden of urinary bladder cancer: An update. *World J. Urol.* 2020, 38, 1895–1904. [CrossRef] [PubMed]
3. Antoni, S.; Ferlay, J.; Soerjomataram, I.; Znaor, A.; Jemal, A.; Bray, F. Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends. *Eur. Urol.* 2017, 71, 96–108. [CrossRef] [PubMed]
4. Saginala, K.; Barsouk, A.; Aluru, J.S.; Rawla, P.; Padala, S.A.; Barsouk, A. Epidemiology of Bladder Cancer. *Med. Sci.* 2020, 8, 15. [CrossRef]
5. Dobosz, P.; Stempor, P.A.; Roszik, J.; Herman, A.; Layani, A.; Berger, R.; Avni, D.; Sidi, Y.; Leibowitz-Amit, R. Checkpoint Genes at the Cancer Side of the Immunological Synapse in Bladder Cancer. *Transl. Oncol.* 2020, 13, 193–200. [CrossRef]
6. Burger, M.; Catto, J.W.F.; Dalbagni, G.; Grossman, H.B.; Herr, H.; Karakiewicz, P.; Kassouf, W.; Kiemeney, L.A.; La Vecchia, C.; Shariat, S.; et al. Epidemiology and Risk Factors of Urothelial Bladder Cancer. *Eur. Urol.* 2013, 63, 234–241. [CrossRef]
7. Rothman, N.; Garcia-Closas, M.; Chatterjee, N.; Malats, N.; Wu, X.; Figueroa, J.D.; Real, F.X.; Van Den Berg, D.; Matullo, G.; Baris, D.; et al. A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. *Nat. Genet.* 2010, 42, 978–984. [CrossRef]
8. Shin, J.H.; Lim, J.S.; Jeon, B.H. Chapter 3—Pathophysiology of Bladder Cancer. In *Bladder Cancer*; Ku, J.H., Ed.; Academic Press: Cambridge, MA, USA, 2018; pp. 33–41.
9. Batlle, E.; Clevers, H. Cancer stem cells revisited. *Nat. Med.* 2017, 23, 1124–1134. [CrossRef]
10. Cortina, C.; Turon, G.; Stork, D.; Hernandez-Momblona, X.; Sevillano, M.; Aguilera, M.; Tosi, S.; Merlos-Suarez, A.; Stephan-Otto Attolini, C.; Sancho, E.; et al. A genome editing approach to study cancer stem cells in human tumors. *EMBO Mol. Med.* 2017, 9, 869–879. [CrossRef]
11. Najafi, M.; Farhood, B.; KMortezaee, K. Cancer stem cells (CSCs) in cancer progression and therapy. *J. Cell Physiol.* 2019, 234, 8381–8395. [CrossRef]
12. Takeishi, S.; Nakayama, K.I. To wake up cancer stem cells, or to let them sleep, that is the question. *Cancer Sci.* 2016, 107, 875–881. [CrossRef]
13. Zhang, Y.; Wang, Z.; Yu, J.; Shi, J.; Wang, C.; Fu, W.; Chen, Z.; Yang, J. Cancer stem-like cells contribute to cisplatin resistance and progression in bladder cancer. *Cancer Lett.* 2012, 322, 70–77. [CrossRef]
14. Abugooma, A.; Elbadawy, M.; Yamawaki, H.; Usui, T.; Sasaki, K. Emerging Roles of Cancer Stem Cells in Bladder Cancer Progression, Tumorigenesis, and Resistance to Chemotherapy: A Potential Therapeutic Target for Bladder Cancer. *Cells* 2020, 9, 235. [CrossRef]
15. Aghaaliani, N.; Rashitchizadeh, N.; Shadpour, P.; Allameh, A.; Mahmooodi, M. Cancer stem cells as a therapeutic target in bladder cancer. *J. Cell Physiol.* 2019, 234, 3197–3206. [CrossRef]
16. He, X.; Xu, C. Immune checkpoint signaling and cancer immunotherapy. *Cell Res.* 2020, 30, 660–669. [CrossRef]
17. Cui, S.; Reichner, J.S.; Mateo, R.B.; Albina, J.E. Activated murine macrophages induce apoptosis in tumor cells through nitric oxide-dependent or -independent mechanisms. *Cancer Res.* 1994, 54, 2462–2467.
18. Noman, M.Z.; Van Moer, K.; Marani, V.; Gemmill, R.M.; Tranchevent, L.O.-C.; Azuaie, F.; Muller, A.; Chouaib, S.; Thiery, J.P.; Berchem, G.; et al. CD47 is a direct target of SNAI1 and ZEB1 and its blockade activates the phagocytosis of breast cancer cells undergoing EMT. *Oncoimmunology* 2018, 7, e1345415. [CrossRef]
19. Chan, K.S.; Volkmer, J.P.; Weissman, I. Cancer stem cells in bladder cancer: A revisited and evolving concept. *Curr. Opin. Urol.* 2010, 20, 393–397. [CrossRef]
20. Hofner, T.; Macher-Goeppinger, S.; Klein, C.; Schillert, A.; Eisen, C.; Wagner, S.; Rigo-Watermeier, T.; Baccelli, I.; Vogel, V.; Trump, A.; et al. Expression and prognostic significance of cancer stem cell markers CD24 and CD44 in urothelial bladder cancer xenografts and patients undergoing radical cystectomy. *Urol. Oncol.* 2014, 32, 678–686. [CrossRef]
21. Manhas, J.; Bhattacharya, A.; Agrawal, S.K.; Gupta, B.; Das, P.; Deo, S.V.S.; Pal, S.; Sen, S. Characterization of cancer stem cells from different grades of human colorectal cancer. *Tumor Biol.* 2016, 37, 14069–14081. [CrossRef]
22. Ren, F.; Sheng, W.-Q.; Du, X. CD133: A cancer stem cells marker, is used in colorectal cancers. *World J. Gastroenterol.* 2013, 19, 2603–2611. [CrossRef]
23. Bentivegna, A.; Conconi, D.; Panzeri, E.; Sala, E.; Bovo, G.; Vigano, P.; Brunelli, S.; Bossi, M.; Tredici, G.; Strada, G.; et al. Biological heterogeneity of putative bladder cancer stem-like cell populations from human bladder transitional cell carcinoma samples. *Cancer Sci.* 2010, 101, 416–424. [CrossRef]
24. Yin, B.; Zeng, Y.; Liu, G.; Wang, X.; Wang, P.; Song, Y. MAGE-A3 is highly expressed in a cancer stem cell-like side population of bladder cancer cells. *Int. J. Clin. Exp. Pathol.* 2014, 7, 2934–2941.
25. Verma, A.; Kapoor, R.; Mittal, R.D. Genetic Variation in CD166 Gene and Its Association with Bladder Cancer Risk in North Indian Population. *Indian J. Clin. Biochem.* 2017, 32, 292–300. [CrossRef]
26. Ooki, A.; VandenBussche, C.J.; Kates, M.; Hahn, N.M.; Matoso, A.; McConkey, D.J.; Bivalacqua, T.J.; Hoque, M.O. CD24 regulates cancer stem cell (CSC)-like traits and a panel of CSC-related molecules serves as a non-invasive urinary biomarker for the detection of bladder cancer. *Br. J. Cancer* 2018, 119, 961–970. [CrossRef]
27. Friederichs, J.; Zeller, Y.; Hafezi-Moghadam, A.; Grone, H.J.; Ley, K.; Altevogt, P. The CD24/P-selectin binding pathway initiates lung arrest of human A125 adenocarcinoma cells. *Cancer Res.* 2000, 60, 6714–6722.
28. Overdevest, J.B.; Thomas, S.; Kristiansen, G.; Hanson, D.E.; Smith, S.C.; Theodorescu, D. CD24 offers a therapeutic target for control of bladder cancer metastasis based on a requirement for lung colonization. *Cancer Res.* 2011, 71, 3802–3811. [CrossRef]
29. Farid, R.M.; Sammour, S.A.-E.; Shehab ElDin, Z.A.; Salman, M.I.; Omran, T.I. Expression of CD133 and CD24 and their different phenotypes in urinary bladder carcinoma. *Cancer Manag. Res.* 2019, 11, 4677–4690. [CrossRef]
30. Hacek, J.; Brisuđa, A.; Babijuk, M.; Zamecnik, J. Expression of cancer stem cells markers in urinary bladder urothelial carcinoma and its precursor lesions. *Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub.* 2021, 165, 316–321. [CrossRef]
56. Schneider, A.K.; Chevalier, M.F.; Derre, L. The multifaceted immune regulation of bladder cancer. *Nat. Rev. Urol.* 2019, 16, 613–630. [CrossRef]

57. Morimoto, J.; Matsumoto, M.; Miyazawa, R.; Yoshiha, H.; Tsuneyama, K.; Matsumoto, M. Aire suppresses CTLA-4 expression from the thymic stroma to control autoimmunity. *Cell Rep.* 2022, 38, 110384. [CrossRef]

58. Lee, S.H.; Hu, W.; Matulay, J.T.; Silva, M.V.; Owczarek, T.B.; Kim, K.; Chua, C.W.; Barlow, L.J.; Kandoth, C.; Williams, A.B.; et al. Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer. *Cell* 2018, 173, 515–528.e17. [CrossRef]

59. Mullenders, J.; de Jongh, E.; Brousalı, A.; Roosen, M.; Blom, J.P.A.; Begthel, H.; Korving, J.; Junes, T.; Kranenburg, O.; Meijer, R.; et al. Mouse and human urothelial cancer organoids: A tool for bladder cancer research. *Proc. Natl. Acad. Sci. USA* 2019, 116, 4567–4574. [CrossRef]

60. Yuki, K.; Cheng, N.; Nakano, M.; Kuo, C.J. Organoid Models of Tumor Immunology. *Trends Immunol.* 2020, 41, 652–664. [CrossRef]

61. Elbadawy, M.; Sato, Y.; Mori, T.; Goto, Y.; Hayashi, K.; Yamanaka, M.; Azakami, D.; Uchide, T.; Fukushima, R.; Yoshida, T.; et al. Anti-tumor effect of trametinib in bladder cancer organoid and the underlying mechanism. *Cancer Biol. Ther.* 2021, 22, 357–371. [CrossRef]

62. Medle, B.; Sjjödahl, G.; Eriksson, P.; Liedberg, F.; Höglund, M.; Bernardo, C. Patient-Derived Bladder Cancer Organoid Models in Tumor Biology and Drug Testing: A Systematic Review. *Cancers* 2022, 14, 2062. [CrossRef]

63. Sawodny, O.; Stenzl, A. Intraoperative Multisensory Tissue Differentiation in Oncology. Available online: https://www.grk2543.uni-stuttgart.de/en/ (accessed on 1 April 2022).

64. Hoffmann, M.J.; Koutsogiannouli, E.; Skowron, M.A.; Pinkermeil, M.; Niegisch, G.; Brandt, A.; Stepanow, S.; Rieder, H.; Schulz, W.A. The New Immortalized Uroepithelial Cell Line HBLAK Contains Defined Genetic Aberrations Typical of Early Stage Urothelial Tumors. *Bladder Cancer* 2016, 2, 449–463. [CrossRef] [PubMed]

65. Paulsen, I.M.; Dimke, H.; Frische, S. A single simple procedure for dewaxing, hydration and heat-induced epitope retrieval (HIER) for immunohistochemistry in formalin fixed paraffin-embedded tissue. *Eur. J. Histochem.* 2015, 59, 2532. [CrossRef] [PubMed]

66. Ausubel, F.M.; Brent, R.; Kingston, R.E.; Moore, D.D.; Seidman, J.G.; Smith, J.A.; Struhl, K. *Short Protocols in Molecular Biology*; John Wiley & Sons: New York, NY, USA, 2002.

67. Rasmussen, R.; Morrison, T.; Herrmann, M.; Wittwer, C. Quantitative PCR by continuous fluorescence monitoring of a double strand DNA specific binding dye. *Biochimica* 1998, 2, 8–11.